УДК 616.12-008.9-008.313.2-08:615.272:612.017.

THE INFLUENCE OF SIMVASTATINE ON THE IMMUNOLOGY PARAMETERS IN PATIENTS WITH METABOLIC SYNDROME IN COMBINATION WITH ATRIAL FIBRILLATION

Akhmedov V.A., Dolgikh V.T., Naumov D.V., Dvornikov V.E.

Omsk state medical academy, Omsk railway hospital

The aim – estimate the influence of simvastatine (simvastole) on the parameters of matrix metalloproteinase-9 and its antagonist – tissue ingibitor of matrix metalloproteinase-1 in patients with metabolic syndrome in combination with paroxizmal atrial fibrillation. *Materials and methods.* The were investigated 60 men with metabolic syndrome in combination with paroxizmal atrial fibrillation. In all patients with immunoassay method investigated the serum level of matrix metalloproteinase-9 and tissue ingibitor of matrix metalloproteinase-1. *Results.* In men with metabolic syndrome in combination with paroxizmal atrial fibrillation there were significant decrease of matrix metalloproteinase-9 activity (P=0,043) were estimated after the therapy with simvastol, and increase of the tissue ingibitor of matrix metalloproteinase-1 activity (P=0,018) were estimated. *Conclusion.* The addition to usual therapy of simvastatine (simvastol) in patients with metabolic syndrome in combination with paroxizmal atrial fibrillation is useful with the pathogenetic position.

KEY WORDS: METABOLIC SYNDROME, MMP-9, TIMP-1, SIMVASTATINE

Literature

1. Akhmedov VA., Dolgikh V.T., Naumov D.V. et al. Metalloproteinaze activity at the patients with metabolic syndrome and atrial fibrillation // Vestnik NGU, Seria Biologia, Klinicheskaya medicina. – 2010. –Vol.8, № 4. –P. 113-118.
2. Hezheva F.M., Mazur N.A. The serum markers of fibrosis at the patients with arterial hypertension // Kardiologia. – 2006. - № 3. – P. 64-67.
3. Cipollone F., Fazia V, Iezzi A. et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity // Circulation. – 2004. – Vol. 109., № 12 – P. 1482-1488.

4. Johnson J.L. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability // Expert. Rev. Cardiovasc. Ther. – 2007. – Vol. 5, № 2. – P. 265-282.
5. Luan Z., Chase A.J., Newby A.C. Statins inhibit secretion of metalloproteinases- 1, -2, -3, and -9 from vascular smooth muscle cells and macrophages // Arterioscler. Thromb. Vasc. Biol. – 2003, - Vol. 23. – P. 769-775.
6. Ohtsuka T. Hamada M., Saeki H. et al. Serum levels of matrix metalloproteinases and tumor necrosis factor-alpha in patients with idiopathic dilated cardiomyopathy and effect of carvedilol on these levels // Am. J. Cardiol. – 2003. – Vol.91., № 8 – P. 1024-1027.
7. Pasterkamp G., Schoneveld A.H., Hijnen D.J. et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery // Atherosclerosis. – 2000. –Vol. 150. – P. 245–253.
8. Porter K.E., Turner N.A. , O Regan N.J. et al. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin // Cardiovasc. Res. – 2004. - № 64. – P. 507-515.

.

Vadim Adil'evich Akhmedov, MD, professor of the Faculty Therapy Department of Omsk State Medical Academy, Omsk, Russia v_akhmedov@mail.ru

Vladimir Terentevich Dolgikh MD, professor The Chief of the Department of Pathofiziology of Omsk State Medical Academy, Omsk, Russia prof_dolgih@mail.ru

Dmitriy Valerievich Naumov, k.m.n. The cardiologist of the cardiology unit of the Omsk Railway hospital

Vadim Erievich Dvornikov, k.m.n. The chief of the cardiology unit of the Omsk Railway hospital okb@omskcity.com.